Barbara L. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Barbara L. Smith has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Michele A. Gadd
Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA
10 shared publicationsRong Tang
Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA; Division of Breast Surgery, Hunan Cancer Hospital, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, China
10 shared publicationsMichelle C. Specht
Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA
9 shared publicationsSuzanne B. Coopey
Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA
9 shared publications- Kevin S. Hughes
Division of Oncologic & Endocrine Surgery, Department of Surgery, Medical University of South Carolina, Charleston, SC
8 shared publications - William Gerald Jr. Austen
From the Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Harvard Medical School
7 shared publications
Latest Publications
- 10 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (5_suppl) , 9
Breast cancer care redesign as an approach to streamline survivorship care: Outcomes and challenges.
9 Background: Optimal follow up care for the 3.1 million breast cancer (BC) survivors in the United States has not been definitively determined. ASCO and NCCN recommend that early stage BC patients have a history and physical by their oncology or primary care provider every 3 to 6 months in the first three years post treatment. Additional visits have not been shown to improve outcomes. However, many patients are seen more frequently, leading to increased healthcare costs. In this context, we developed and implemented a BC care redesign algorithm (BCCRA) to reduce redundant follow up. Methods: The BCCRA multidisciplinary team recommended BC survivors be seen by an oncology provider every 6 months for the first five years post treatment and annually thereafter. Retrospective chart review was conducted to evaluate BCCRA adherence from November 2014 to November of 2015. Patients were deemed ineligible if there was a medically necessary reason for visits outside of the BCCRA such as reconstruction, ongoing treatment or clinical trial participation. Eligible charts were analyzed for adherence. For survivors who did not adhere, charts were analyzed for outcome of additional visits. Results: 116 patient charts reviewed and 72 (62.1%) were deemed ineligible. Of the remaining 44 survivors, 26 (59.1 %) adhered and 18 (40.91%) did not adhere. Of the 18 survivors who did not adhere, six had visits due to clinical concern and 12 had visits due to patient or provider preference. Of the 6 patients who had visits for clinical concern, 4 resulted in a change in the patient’s medical management (CMM). Of the 12 patients who had visits due to patient/provider preference, 2 resulted in a CMM. Conclusions: Despite buy-in from a motivated multidisciplinary team, there were challenges to implementing the BCCRA. 62.1% of patients were ineligible and there was a significant proportion of patients/providers who chose more frequent visit schedules. However, the BCCRA had 59.1% adherence which could result in cost reduction and increased flexibility in oncologists’ schedules. Further evaluation of the model is needed to validate these claims.
- 10 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (5_suppl) , 9
Breast cancer care redesign as an approach to streamline survivorship care: Outcomes and challenges.
9 Background: Optimal follow up care for the 3.1 million breast cancer (BC) survivors in the United States has not been definitively determined. ASCO and NCCN recommend that early stage BC patients have a history and physical by their oncology or primary care provider every 3 to 6 months in the first three years post treatment. Additional visits have not been shown to improve outcomes. However, many patients are seen more frequently, leading to increased healthcare costs. In this context, we developed and implemented a BC care redesign algorithm (BCCRA) to reduce redundant follow up. Methods: The BCCRA multidisciplinary team recommended BC survivors be seen by an oncology provider every 6 months for the first five years post treatment and annually thereafter. Retrospective chart review was conducted to evaluate BCCRA adherence from November 2014 to November of 2015. Patients were deemed ineligible if there was a medically necessary reason for visits outside of the BCCRA such as reconstruction, ongoing treatment or clinical trial participation. Eligible charts were analyzed for adherence. For survivors who did not adhere, charts were analyzed for outcome of additional visits. Results: 116 patient charts reviewed and 72 (62.1%) were deemed ineligible. Of the remaining 44 survivors, 26 (59.1 %) adhered and 18 (40.91%) did not adhere. Of the 18 survivors who did not adhere, six had visits due to clinical concern and 12 had visits due to patient or provider preference. Of the 6 patients who had visits for clinical concern, 4 resulted in a change in the patient’s medical management (CMM). Of the 12 patients who had visits due to patient/provider preference, 2 resulted in a CMM. Conclusions: Despite buy-in from a motivated multidisciplinary team, there were challenges to implementing the BCCRA. 62.1% of patients were ineligible and there was a significant proportion of patients/providers who chose more frequent visit schedules. However, the BCCRA had 59.1% adherence which could result in cost reduction and increased flexibility in oncologists’ schedules. Further evaluation of the model is needed to validate these claims.
- 1 June 2016
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 222 (6) , 1149-1155
Positive Nipple Margins in Nipple-Sparing Mastectomies: Rates, Management, and Oncologic Safety
BACKGROUND: When a nipple margin of a nipple-sparing mastectomy (NSM) contains malignancy, current practice includes removal of the nipple or nipple areola complex (NAC). We evaluated rates and trends of positive nipple margins, subsequent management, and oncologic outcomes. STUDY DESIGN: A retrospective chart review of all NSM at our institution from 2007 to 2014 was performed. A descriptive analysis was performed of patients with positive nipple/subareolar margins. RESULTS: Among 1,326 NSM, 43 of 642 (6.7%) therapeutic and 3 of 684 (0.4%) prophylactic NSM had positive nipple margins. Nipple or NAC excision was performed for 39 of 46 (85%) positive nipple margins: 20 of 39 (51%) had nipple only and 19 of 39 (49%) had the entire NAC excised. Practice evolved to remove only the nipple and retain the areola for positive nipple margins: in 2007 to 2011, 7 of 17 (41%) underwent nipple-only excision compared with 14 of 22 (64%) in 2012 to 2014. Among 39 excised nipples/NAC, 28 (72%) contained no residual malignancy, while 8 contained ductal carcinoma in situ (DCIS), 2 had invasive lobular carcinoma, and 1 had invasive ductal carcinoma. With experience, rates of positive nipple margins for therapeutic NSM decreased from 11% (17 of 160) in 2007 to 2011 to 5.4% (26 of 482) in 2012 to 2014 (p < 0.05). At 36 month median follow-up, there were no recurrences in the nipple/NAC. CONCLUSIONS: Early results suggest that excision of the nipple with retention of the areola is a safe approach for management of a positive nipple margin after NSM. With experience, low rates of positive nipple margins are possible in therapeutic NSM. Overall risk of nipple/NAC recurrence after NSM remains extremely low.
- 1 June 2016
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 222 (6) , 1149-1155
Positive Nipple Margins in Nipple-Sparing Mastectomies: Rates, Management, and Oncologic Safety
BACKGROUND: When a nipple margin of a nipple-sparing mastectomy (NSM) contains malignancy, current practice includes removal of the nipple or nipple areola complex (NAC). We evaluated rates and trends of positive nipple margins, subsequent management, and oncologic outcomes. STUDY DESIGN: A retrospective chart review of all NSM at our institution from 2007 to 2014 was performed. A descriptive analysis was performed of patients with positive nipple/subareolar margins. RESULTS: Among 1,326 NSM, 43 of 642 (6.7%) therapeutic and 3 of 684 (0.4%) prophylactic NSM had positive nipple margins. Nipple or NAC excision was performed for 39 of 46 (85%) positive nipple margins: 20 of 39 (51%) had nipple only and 19 of 39 (49%) had the entire NAC excised. Practice evolved to remove only the nipple and retain the areola for positive nipple margins: in 2007 to 2011, 7 of 17 (41%) underwent nipple-only excision compared with 14 of 22 (64%) in 2012 to 2014. Among 39 excised nipples/NAC, 28 (72%) contained no residual malignancy, while 8 contained ductal carcinoma in situ (DCIS), 2 had invasive lobular carcinoma, and 1 had invasive ductal carcinoma. With experience, rates of positive nipple margins for therapeutic NSM decreased from 11% (17 of 160) in 2007 to 2011 to 5.4% (26 of 482) in 2012 to 2014 (p < 0.05). At 36 month median follow-up, there were no recurrences in the nipple/NAC. CONCLUSIONS: Early results suggest that excision of the nipple with retention of the areola is a safe approach for management of a positive nipple margin after NSM. With experience, low rates of positive nipple margins are possible in therapeutic NSM. Overall risk of nipple/NAC recurrence after NSM remains extremely low.
- 20 May 2016
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 23 (11) , 3453-3458
Should New “No Ink On Tumor” Lumpectomy Margin Guidelines be Applied to Ductal Carcinoma In Situ (DCIS)? A Retrospective Review Using Shaved Cavity Margins
Background No consensus exists for clear margins for breast-conserving surgery for pure ductal carcinoma in situ (DCIS). We examined the implications of applying a “no ink on tumor” standard for pure...
- 20 May 2016
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 23 (11) , 3453-3458
Should New “No Ink On Tumor” Lumpectomy Margin Guidelines be Applied to Ductal Carcinoma In Situ (DCIS)? A Retrospective Review Using Shaved Cavity Margins
Background No consensus exists for clear margins for breast-conserving surgery for pure ductal carcinoma in situ (DCIS). We examined the implications of applying a “no ink on tumor” standard for pure...
- 1 February 2016
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 89 (1058) , 20150581
Intraoperative micro-computed tomography (micro-CT): a novel method for determination of primary tumour dimensions in breast cancer specimens
Objectives:Micro-CT is a promising modality to determine breast tumour size in three dimensions in intact lumpectomy specimens. We compared the accuracy of tumour size measurements using specimen micro-CT with measurements using multimodality pre-operative imaging.Methods:A tabletop micro-CT was used to image breast lumpectomy specimens. The largest tumour dimension on three-dimensional reconstructed micro-CT images of the specimen was compared with the measurements determined by pre-operative mammography, ultrasound and MRI. The largest dimension of pathologic invasive cancer size was used as the gold standard reference to assess the accuracy of imaging assessments.Results:50 invasive breast cancer specimens in 50 patients had micro-CT imaging. 42 were invasive ductal carcinoma, 6 were invasive lobular carcinoma and 2 were other invasive cancer. Median patient age was 63 years (range 33–82 years). When compared with the largest pathologic tumour dimension, micro-CT measurements had the best correlation c...
- 1 February 2016
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 89 (1058) , 20150581
Intraoperative micro-computed tomography (micro-CT): a novel method for determination of primary tumour dimensions in breast cancer specimens
Objectives:Micro-CT is a promising modality to determine breast tumour size in three dimensions in intact lumpectomy specimens. We compared the accuracy of tumour size measurements using specimen micro-CT with measurements using multimodality pre-operative imaging.Methods:A tabletop micro-CT was used to image breast lumpectomy specimens. The largest tumour dimension on three-dimensional reconstructed micro-CT images of the specimen was compared with the measurements determined by pre-operative mammography, ultrasound and MRI. The largest dimension of pathologic invasive cancer size was used as the gold standard reference to assess the accuracy of imaging assessments.Results:50 invasive breast cancer specimens in 50 patients had micro-CT imaging. 42 were invasive ductal carcinoma, 6 were invasive lobular carcinoma and 2 were other invasive cancer. Median patient age was 63 years (range 33–82 years). When compared with the largest pathologic tumour dimension, micro-CT measurements had the best correlation c...
- 1 October 2015
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 136, 112-113
Three Years Experience with Absorbable Mesh in Single-Stage Breast Reconstruction
- 1 October 2015
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 136, 112-113
Three Years Experience with Absorbable Mesh in Single-Stage Breast Reconstruction
- 23 July 2015
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 22 (10) , 3331-3337
Nipple-Sparing Mastectomy in Irradiated Breasts: Selecting Patients to Minimize Complications
Background Nipple-sparing mastectomies (NSM) are increasingly common because of their cosmetic advantage. Radiotherapy (RT) has been a relative contraindication to immediate reconstruction because of...
- 23 July 2015
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 22 (10) , 3331-3337
Nipple-Sparing Mastectomy in Irradiated Breasts: Selecting Patients to Minimize Complications
Background Nipple-sparing mastectomies (NSM) are increasingly common because of their cosmetic advantage. Radiotherapy (RT) has been a relative contraindication to immediate reconstruction because of...
- 1 July 2015
- Published by Elsevier in The American Journal of Surgery
- Vol. 210 (1) , 93-98
Lumpectomy specimen margins are not reliable in predicting residual disease in breast conserving surgery
- 1 July 2015
- Published by Elsevier in The American Journal of Surgery
- Vol. 210 (1) , 93-98
Lumpectomy specimen margins are not reliable in predicting residual disease in breast conserving surgery
- 1 April 2015
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 135 (4) , 1256
Abstract P93: Three Years Experience with Absorbable Mesh... : Plastic and Reconstructive Surgery
- 1 April 2015
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 135 (4) , 1256
Abstract P93: Three Years Experience with Absorbable Mesh... : Plastic and Reconstructive Surgery
- 1 April 2015
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 135, 1256
Abstract P93
- 1 April 2015
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 135, 1256
Abstract P93
- 2 June 2014
- Published by Hindawi Limited in The Breast Journal
- Vol. 20 (4) , 402-407
Management of Positive Sub-areolar/Nipple Duct Margins in Nipple-Sparing Mastectomies
We evaluated management of positive sub-areolar/nipple duct margins in nipple-sparing mastectomies (NSM) at our institution. Retrospective chart review of all NSM from January 2007 to April 2012 was performed and patient, tumor, and treatment information was collected. Sub-areolar/nipple duct margins included ductal tissue from within the nipple. Of 438 NSM, 22 (5%) had positive sub-areolar/nipple duct margins; 21 of 220 cancer-bearing breasts (10%) and 1 of 218 prophylactic mastectomies (0.5%). Positive margins included four with invasive lobular carcinoma and 18 with ductal carcinoma in situ (DCIS). Management included removal of eight nipples and nine nipple areola complexes (NAC). Four of 17 nipple/NAC specimens had evidence of residual DCIS and none had residual invasive cancer. The majority of nipple/NAC specimens excised for a positive margin had no residual malignancy. Future studies are needed to determine the extent of NAC tissue removal required for positive margins.
- 2 June 2014
- Published by Hindawi Limited in The Breast Journal
- Vol. 20 (4) , 402-407
Management of Positive Sub-areolar/Nipple Duct Margins in Nipple-Sparing Mastectomies
We evaluated management of positive sub-areolar/nipple duct margins in nipple-sparing mastectomies (NSM) at our institution. Retrospective chart review of all NSM from January 2007 to April 2012 was performed and patient, tumor, and treatment information was collected. Sub-areolar/nipple duct margins included ductal tissue from within the nipple. Of 438 NSM, 22 (5%) had positive sub-areolar/nipple duct margins; 21 of 220 cancer-bearing breasts (10%) and 1 of 218 prophylactic mastectomies (0.5%). Positive margins included four with invasive lobular carcinoma and 18 with ductal carcinoma in situ (DCIS). Management included removal of eight nipples and nine nipple areola complexes (NAC). Four of 17 nipple/NAC specimens had evidence of residual DCIS and none had residual invasive cancer. The majority of nipple/NAC specimens excised for a positive margin had no residual malignancy. Future studies are needed to determine the extent of NAC tissue removal required for positive margins.